KIMBERLY GRANA: Open Payments
NPI 1538539614 · BELLEVILLE, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,886 in 139 payments from 21 companies in 2025. Trend: 2023 $2,433 · 2024 $3,076 · 2025 $2,886
Food & beverage: $2,886
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $726 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $531 |
| GENZYME CORPORATION | 5 | $289 |
| PFIZER INC. | 14 | $229 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $189 |
| Boston Scientific Corporation | 2 | $164 |
| Madrigal Pharmaceuticals | 7 | $124 |
| Gilead Sciences, Inc. | 5 | $104 |
| Aimmune Therapeutics, Inc. | 5 | $98 |
| QOL Medical, LLC | 4 | $68 |
Products named: RINVOQ, ENTYVIO, DUPIXENT, XIFAXAN, WATCHMAN FLX, CREON, VELSIPITY, REZDIFFRA.
Industry payments across IL — which companies pay providers there.
